Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer

Published:2016-03-12 Issue:1 Volume:139 Page:187-193
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Verhoeff S.R.¹,van Erning F.N.²³,Lemmens V.E.P.P.²³,de Wilt J.H.W.⁴,Pruijt J.F.M.¹

Affiliation:

1. Department of Internal Medicine; Jeroen Bosch Hospital; ‘s-Hertogenbosch The Netherlands

2. Department of Research; Netherlands Comprehensive Cancer Organisation (IKNL); Eindhoven The Netherlands

3. Department of Public Health; Erasmus MC University Medical Centre; Rotterdam The Netherlands

4. Department of Surgery; Radboud University Nijmegen Medical Centre; Nijmegen The Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference31 articles.

1. Netherlands Cancer Registry 2015 www.cijfersoverkanker.nl

2. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases;Geest;Clin Exp Metastasis,2015

3. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators;Lancet,1995

4. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;Andre;J Clin Oncol,2009

5. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer;Benson;J Clin Oncol,2004

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Two‐Step Framework for Validating Causal Effect Estimates;Pharmacoepidemiology and Drug Safety;2024-09

2. Integrated multiplex analysis of cell death regulators in stage II colorectal cancer suggests patients with ‘persister’ cell profiles fail to benefit from adjuvant chemotherapy;BMJ Oncology;2024-08

3. Evaluation of CD3 and CD8 T-Cell Immunohistochemistry for Prognostication and Prediction of Benefit From Adjuvant Chemotherapy in Early-Stage Colorectal Cancer Within the QUASAR Trial;Journal of Clinical Oncology;2024-07-31

4. Unraveling the Interplay of KRAS, NRAS, BRAF, and Micro-Satellite Instability in Non-Metastatic Colon Cancer: A Systematic Review;Diagnostics;2024-05-12

5. Value of Real-World Evidence for Treatment Selection: A Case Study in Colon Cancer;JCO Clinical Cancer Informatics;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3